Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ANRO NASDAQ:REPL NASDAQ:TLSA NASDAQ:ZVRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANROAlto Neuroscience$18.35-8.4%$22.82$2.15▼$28.44$702.93M1.22310,102 shs414,098 shsREPLReplimune Group$9.47-4.1%$5.11$1.50▼$13.24$814.99M0.919.04 million shs4.60 million shsTLSATiziana Life Sciences$1.24-2.4%$1.34$1.08▼$2.60$161.62M0.44269,944 shs84,317 shsZVRAZevra Therapeutics$10.61-5.0%$10.32$7.16▼$13.16$660.32M0.911.90 million shs2.12 million shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANROAlto Neuroscience+5.96%-0.94%-21.24%-3.38%+721.68%REPLReplimune Group-1.10%+110.90%+243.90%+22.30%+1.86%TLSATiziana Life Sciences+7.63%-13.01%-11.19%-8.63%-11.19%ZVRAZevra Therapeutics+1.92%-2.02%+5.28%+24.39%+24.80%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANROAlto Neuroscience$18.35-8.4%$22.82$2.15▼$28.44$702.93M1.22310,102 shs414,098 shsREPLReplimune Group$9.47-4.1%$5.11$1.50▼$13.24$814.99M0.919.04 million shs4.60 million shsTLSATiziana Life Sciences$1.24-2.4%$1.34$1.08▼$2.60$161.62M0.44269,944 shs84,317 shsZVRAZevra Therapeutics$10.61-5.0%$10.32$7.16▼$13.16$660.32M0.911.90 million shs2.12 million shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANROAlto Neuroscience+5.96%-0.94%-21.24%-3.38%+721.68%REPLReplimune Group-1.10%+110.90%+243.90%+22.30%+1.86%TLSATiziana Life Sciences+7.63%-13.01%-11.19%-8.63%-11.19%ZVRAZevra Therapeutics+1.92%-2.02%+5.28%+24.39%+24.80%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANROAlto Neuroscience 2.70Moderate Buy$35.2592.08% UpsideREPLReplimune Group 1.70Reduce$4.88-48.52% DownsideTLSATiziana Life Sciences 1.00SellN/AN/AZVRAZevra Therapeutics 2.78Moderate Buy$23.33119.92% UpsideCurrent Analyst Ratings BreakdownLatest TLSA, REPL, ANRO, and ZVRA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/3/2026REPLReplimune Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/1/2026REPLReplimune Group WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$2.00 ➝ $6.005/29/2026TLSATiziana Life Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/29/2026REPLReplimune Group JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeUnderweight ➝ Neutral$8.005/27/2026ANROAlto Neuroscience HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$50.005/22/2026ZVRAZevra Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy (B-) ➝ Hold (C)5/22/2026ANROAlto Neuroscience Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform5/18/2026ANROAlto Neuroscience Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$38.00 ➝ $36.005/14/2026ANROAlto Neuroscience WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$21.00 ➝ $24.005/11/2026ANROAlto Neuroscience HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$50.005/8/2026REPLReplimune Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)(Data available from 6/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANROAlto NeuroscienceN/AN/AN/AN/A$4.87 per shareN/AREPLReplimune GroupN/AN/AN/AN/A$5.40 per shareN/ATLSATiziana Life SciencesN/AN/AN/AN/AN/AN/AZVRAZevra Therapeutics$106.47M5.89$0.90 per share11.81$2.75 per share3.86Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANROAlto Neuroscience-$63.24M-$2.42N/AN/AN/AN/A-47.22%-38.81%8/12/2026 (Estimated)REPLReplimune Group-$247.30M-$3.44N/AN/AN/AN/A-102.69%-72.22%7/30/2026 (Estimated)TLSATiziana Life Sciences-$18.43MN/AN/AN/AN/AN/AN/AN/A6/18/2026 (Estimated)ZVRAZevra Therapeutics$83.23M$1.998.808.92N/A101.58%51.49%28.86%8/11/2026 (Estimated)Latest TLSA, REPL, ANRO, and ZVRA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026ANROAlto Neuroscience-$0.56-$0.80-$0.24-$0.80N/AN/A5/6/2026Q1 2026ZVRAZevra Therapeutics$0.06$0.18+$0.12$0.60$31.96 million$36.22 million5/1/2026Q4 2025TLSATiziana Life SciencesN/A-$0.2750N/A-$0.2750N/AN/A3/16/2026Q4 2025ANROAlto Neuroscience-$0.56-$0.45+$0.11-$0.45N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthANROAlto NeuroscienceN/AN/AN/AN/AN/AREPLReplimune GroupN/AN/AN/AN/AN/ATLSATiziana Life SciencesN/AN/AN/AN/AN/AZVRAZevra TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANROAlto Neuroscience0.0720.5220.52REPLReplimune Group0.335.605.60TLSATiziana Life SciencesN/A0.760.76ZVRAZevra TherapeuticsN/A4.894.84Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANROAlto NeuroscienceN/AREPLReplimune Group92.53%TLSATiziana Life SciencesN/AZVRAZevra Therapeutics35.03%Insider OwnershipCompanyInsider OwnershipANROAlto Neuroscience11.25%REPLReplimune Group5.20%TLSATiziana Life Sciences39.82%ZVRAZevra Therapeutics2.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANROAlto NeuroscienceN/A35.09 million31.15 millionN/AREPLReplimune Group21082.57 million78.28 millionOptionableTLSATiziana Life Sciences8127.26 million76.58 millionOptionableZVRAZevra Therapeutics2059.12 million57.70 millionOptionableTLSA, REPL, ANRO, and ZVRA HeadlinesRecent News About These CompaniesZevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Rating of "Moderate Buy" by AnalystsJune 5 at 3:15 AM | americanbankingnews.comZevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)May 29, 2026 | globenewswire.comZevra Therapeutics' (NASDAQ:ZVRA) Earnings Aren't As Good As They AppearMay 13, 2026 | finance.yahoo.comZevra Therapeutics to Present at the H.C. Wainwright BioConnect Investor ConferenceMay 12, 2026 | globenewswire.comAnalysts Are Bullish on Top Healthcare Stocks: Zevra Therapeutics (ZVRA), Medicus Pharma Ltd (MDCX)May 11, 2026 | theglobeandmail.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Rating of "Moderate Buy" by BrokeragesMay 11, 2026 | marketbeat.comHC Wainwright Analysts Increase Earnings Estimates for ZVRAMay 11, 2026 | marketbeat.comZevra Therapeutics Earnings Call Highlights Growth PivotMay 10, 2026 | tipranks.comZevra Therapeutics, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen NextMay 9, 2026 | finance.yahoo.comResearch Analysts Offer Predictions for ZVRA Q2 EarningsMay 8, 2026 | marketbeat.comZevra Therapeutics: Q1 Earnings SnapshotMay 7, 2026 | chron.comZevra (ZVRA) Q1 2026 Earnings Call TranscriptMay 7, 2026 | fool.comIs It Too Late To Consider Zevra Therapeutics (ZVRA) After The Recent Share Price Surge?May 7, 2026 | finance.yahoo.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Q1 2026 Earnings Call TranscriptMay 7, 2026 | insidermonkey.comZevra Therapeutics Q1 Earnings Call HighlightsMay 7, 2026 | marketbeat.comZevra Therapeutics, Inc. (ZVRA) Q1 2026 Earnings Call TranscriptMay 7, 2026 | seekingalpha.comZevra Therapeutics (ZVRA) Q1 Earnings and Revenues Surpass EstimatesMay 6, 2026 | zacks.comZevra Therapeutics (NASDAQ:ZVRA) Announces Earnings ResultsMay 6, 2026 | marketbeat.comZevra Reports First Quarter 2026 Financial Results and Corporate UpdateMay 6, 2026 | globenewswire.comZevra Therapeutics Announces Details for Q1 2026 Financial Results CallApril 23, 2026 | markets.businessinsider.comZevra Ties NPC Testing Push To Valuation Gap And New CFOMarch 22, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 2026Before the Moon Base Gets Built, These 4 Companies WinBy Thomas Hughes | May 11, 2026IonQ Just Posted a Breakout Quarter—But 1 Problem RemainsBy Nathan Reiff | May 7, 2026The Smart Glasses Gold Rush Is Leaving Old-School Eyewear BehindBy Jeffrey Neal Johnson | May 24, 2026The Power Grid Is Dying—Is It Time to Buy Its Replacement?By Jeffrey Neal Johnson | May 15, 2026TLSA, REPL, ANRO, and ZVRA Company DescriptionsAlto Neuroscience NYSE:ANRO$18.35 -1.68 (-8.38%) Closing price 03:59 PM EasternExtended Trading$18.20 -0.15 (-0.83%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.Replimune Group NASDAQ:REPL$9.47 -0.40 (-4.05%) Closing price 04:00 PM EasternExtended Trading$9.46 -0.01 (-0.05%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.Tiziana Life Sciences NASDAQ:TLSA$1.24 -0.03 (-2.36%) Closing price 04:00 PM EasternExtended Trading$1.25 +0.01 (+0.40%) As of 07:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.Zevra Therapeutics NASDAQ:ZVRA$10.61 -0.56 (-5.01%) Closing price 04:00 PM EasternExtended Trading$10.60 -0.01 (-0.09%) As of 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? Buy the Dip? Broadcom's AI Moat Is Wider Than Ever The Market Has Ollie’s Bargain Outlet Completely Wrong Broadcom's Whiplash: Shares Tank After Pre-Earnings Surge Navitas: NVIDIA’s AI Power Broker? Macy's Delivers Strong Q1, Raises Outlook, but Wall Street Remains Cautious NVIDIA's New Power Play: Why Fluence Is Surging Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
